热门资讯> 正文

KalVista Pharmaceuticals GAAP每股收益为-1.12美元，亏损0.17美元，收入为143万美元，亏损0.66万美元

2025-09-11 19:03

KalVista Pharmaceuticals press release (NASDAQ:KALV): Q1 GAAP EPS of -$1.12 misses by $0.17.
Revenue of $1.43M misses by $0.66M.
As of July 31, 2025, the Company had cash, cash equivalents and marketable securities of approximately $191.5 million.

More on KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc. (KALV) Presents At Cantor Global Healthcare Conference 2025 Transcript
KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade)
KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning
KalVista, Biogen, Ionis get EU positive opinions for key drugs
KalVista Pharmaceuticals rises after FDA nod for Ekterly

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。